Tirzepatide is marketed as ZEPBOUND in this label and is a dual GIP and GLP-1 receptor agonist for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. It is used with reduced-calorie diet and increased physical activity. U.S. labeling lists initial approval in 2023 with major updates through 2025.
A retrospective cohort study of 14,118 matched pairs found tirzepatide associated with lower risks of stroke and death than other GLP-1 receptor agonists in patients with atrial fibrillation and type 2 diabetes. Absolute differences were 2.1 percentage points for stroke and 6.2 for mortality at one year. Randomized trials are needed before recommendations change.
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
The FDA proposes to remove three GLP-1 drugs from the bulk compounding list as adverse events near 2,000 and Senator Tom Cotton demands a probe into Chinese APIs in compounded meds. Shortages have largely resolved, but safety and innovation concerns persist.
The FDA moved to exclude semaglutide, tirzepatide and liraglutide from its 503B compounding list. Eli Lilly won U.S. approval for its oral pill Foundayo, and Novo Nordisk sued Lilly over allegedly misleading weight-loss ads.
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07782359 |
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib |
NOT_YET_RECRUITING | PHASE1 |
| NCT07756359 |
Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07747805 |
GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD |
NOT_YET_RECRUITING | PHASE2 |
| NCT07738276 |
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity |
NOT_YET_RECRUITING | PHASE3 |
| NCT07734870 |
Tirzepatide for Treatment of CCCA |
NOT_YET_RECRUITING | PHASE2 |
| NCT07734792 |
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07715929 |
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients |
NOT_YET_RECRUITING | PHASE4 |
| NCT07707778 |
Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT07701005 |
Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity |
COMPLETED | |
| NCT07697391 |
AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE4 |
